JJIJ
ACET icon

Johnson & Johnson Innovation - JJDC’s Adicet Bio ACET Stock Holding History

Johnson & Johnson Innovation - JJDC’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$7.5M Hold
45,559
– – 0.77% 11
2021
Q1 		$9.54M Buy
45,559
+4,142
+10% +$951K 1.23% 9
2020
Q4 		$9.31M Hold
41,417
– – 1.2% 8
2020
Q3 		$7.88M Buy
+41,417
New +$10.5M 1.59% 8

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's ACET Position: Q2 2021 in Review

Johnson & Johnson Innovation - JJDC held its Adicet Bio (ACET) position steady in Q2 2021 at 45,559 shares worth $7.5M. The position accounts for 0.77% of the portfolio, ranked #11.

Johnson & Johnson Innovation - JJDC first reported a position in ACET in Q3 2020 and has held it in 4 quarters since. The position peaked at $9.54M in Q1 2021. 65 funds tracked by Wall St. Rank hold ACET as of Q2 2021.

  • Johnson & Johnson Innovation - JJDC held 45,559 shares of Adicet Bio worth $7.5M as of Q2 2021.
  • Johnson & Johnson Innovation - JJDC left its Adicet Bio share count unchanged in Q2 2021.
  • Adicet Bio made up 0.77% of Johnson & Johnson Innovation - JJDC's portfolio in Q2 2021, its #11 holding.
  • Johnson & Johnson Innovation - JJDC first reported a position in Adicet Bio in Q3 2020 and has held it in 4 quarters since.
  • Johnson & Johnson Innovation - JJDC's Adicet Bio position peaked at $9.54M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2021.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2021, filed 3 Aug 2021.